Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095 | Zendy

Jeffrey T. Schouten | Zendy; Amy Krambrink | Zendy; Heather J. Ribaudo | Zendy; Anne Kmack | Zendy; Nancy R. Webb | Zendy; Cecilia M. Shikuma | Zendy; Daniel R. Kuritzkes | Zendy; Roy M. Gulick | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095

Author(s) -

Jeffrey T. Schouten,

Amy Krambrink,

Heather J. Ribaudo,

Anne Kmack,

Nancy R. Webb,

Cecilia M. Shikuma,

Daniel R. Kuritzkes,

Roy M. Gulick

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/650539

Subject(s) - nevirapine , efavirenz , medicine , adverse effect , clinical trial , toxicity , reverse transcriptase inhibitor , pharmacology , human immunodeficiency virus (hiv) , sida , virology , antiretroviral therapy , viral load , viral disease

In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research